Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Feb 23, 2024 12:14pm
94 Views
Post# 35895839

RE:RE:RE:Why ?

RE:RE:RE:Why ?AT the end of the day it does not matter if  people do not want to participate.  Either  relative to privatization or a sale!!  If  the insiders have enough votes  , thats what happens and everyone gets paid the same money per share.

A buy out would likely be better as all shareholders get the same  price.  If however, they take it private , then  minor shareholders may get  bought out at a set price  and  the 'private'  company  can then be sold by the insiders  for a greater price??

Maybe part of the  delay is getting all the  details of the transactiion  worked out  OR  getting enough votes to get whatever done??

Think  our  only recourse is  WAIT and SEE.

GLTA
<< Previous
Bullboard Posts
Next >>